Atlas Trials

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC

Clinical trial NCT04875585 · RECRUITING

Trial details

NCT number
NCT04875585
Sponsor
Medical University Innsbruck
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2021-05-12
Primary completion
2023-12-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.